Participated · Equity · Jul 2025

The Blue Box develops a non-invasive, urine-based breast cancer screening test that uses a chemical sensor to capture volatile organic compounds (VOCs) and a proprietary AI algorithm to recognise cancer-specific patterns. The test is intended for use in gynaecology offices and as part of national screening programs, addressing limitations of mammography particularly for women with dense breasts. The company says its pattern-based approach outperforms mammography in sensitivity and requires no radiation or pain. The fresh capital will accelerate European clinical trials, support manufacturing of medical-grade devices, and fund technical documentation to meet regulatory requirements. Management aims to achieve CE marking by the end of 2026 and launch the clinical study program soon. The product is positioned as a scalable solution to increase early detection and reduce barriers to access for millions of women. BlueBox has developed a non‑invasive diagnostic system that detects breast cancer from a urine sample, offering a painless, no‑radiation alternative to mammography. The company reports higher sensitivity (88.33% vs 56.10%) and higher accuracy (83.32% vs 70.40%) than mammography for women under 50, potentially identifying about 30% more early tumors in that group. The technology is designed to avoid costly lab machinery and specialized personnel, making testing faster, lower‑cost, and more accessible. BlueBox has established clinical partnerships with several leading Spanish hospitals, including Hospital Quirónsalud, Hospital Universitario La Paz, Clínica Dexeus Mujer, Clínica Teknon, Hospital Universitario Sant Joan and Hospital Universitario Joan XXIII. Funds from the recent raise will be used to run clinical trials and obtain CE certification. BlueBox plans to enter the market in 2025 targeting gynecological clinics in Spain.